Diamedica Therapeutics Stock Analysis
| DMAC Stock | USD 4.57 0.38 7.68% |
DiaMedica Therapeutics is overvalued with Real Value of 3.84 and Target Price of 8.0. The main objective of DiaMedica Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what DiaMedica Therapeutics is worth, separate from its market price. There are two main types of DiaMedica Therapeutics' stock analysis: fundamental analysis and technical analysis.
The DiaMedica Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and DiaMedica Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
DiaMedica |
DiaMedica Stock Analysis Notes
About 26.0% of the company shares are held by company insiders. The book value of DiaMedica Therapeutics was currently reported as 0.95. The company recorded a loss per share of 0.6. DiaMedica Therapeutics last dividend was issued on the 15th of November 2018. The entity had 1:20 split on the 15th of November 2018. DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Diamedica Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. To learn more about DiaMedica Therapeutics call Dietrich MBA at 763 496 5454 or check out https://www.diamedica.com.DiaMedica Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. DiaMedica Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding DiaMedica Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| DiaMedica Therapeutics generated a negative expected return over the last 90 days | |
| DiaMedica Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (24.44 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| DiaMedica Therapeutics currently holds about 38.44 M in cash with (22.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.45. | |
| Roughly 26.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: DiaMedica Therapeutics Inc Q4 2024 Earnings Call Highlights Strong Financial Position ... |
DiaMedica Therapeutics Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to DiaMedica Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
DiaMedica Largest EPS Surprises
Earnings surprises can significantly impact DiaMedica Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-08 | 2024-03-31 | -0.16 | -0.14 | 0.02 | 12 | ||
2023-08-14 | 2023-06-30 | -0.18 | -0.16 | 0.02 | 11 | ||
2020-08-11 | 2020-06-30 | -0.15 | -0.17 | -0.02 | 13 |
DiaMedica Therapeutics Environmental, Social, and Governance (ESG) Scores
DiaMedica Therapeutics' ESG score is a quantitative measure that evaluates DiaMedica Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of DiaMedica Therapeutics' operations that may have significant financial implications and affect DiaMedica Therapeutics' stock price as well as guide investors towards more socially responsible investments.
DiaMedica Therapeutics Thematic Classifications
In addition to having DiaMedica Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | Pharmaceutical ProductsUSA Equities from Pharmaceutical Products industry as classified by Fama & French |
DiaMedica Stock Institutional Investors
| Shares | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 87.4 K | State Street Corp | 2024-12-31 | 85 K | Millennium Management Llc | 2024-12-31 | 84.8 K | 683 Capital Management Llc | 2024-12-31 | 76.1 K | Ronald Blue Trust, Inc. | 2024-12-31 | 69.1 K | Goldman Sachs Group Inc | 2024-12-31 | 68.9 K | Jane Street Group Llc | 2024-12-31 | 42.2 K | Citigroup Inc | 2024-12-31 | 38.5 K | Catalyst Financial Partners Llc | 2024-12-31 | 38.5 K | Cooperman Leon G | 2024-12-31 | 1.6 M | Vanguard Group Inc | 2024-12-31 | 1.2 M |
DiaMedica Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 195.85 M.DiaMedica Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.53) | (0.55) | |
| Return On Capital Employed | (0.48) | (0.50) | |
| Return On Assets | (0.53) | (0.55) | |
| Return On Equity | (0.60) | (0.63) |
Management Efficiency
DiaMedica Therapeutics has return on total asset (ROA) of (0.3318) % which means that it has lost $0.3318 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5327) %, meaning that it created substantial loss on money invested by shareholders. DiaMedica Therapeutics' management efficiency ratios could be used to measure how well DiaMedica Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of March 26, 2025, Return On Tangible Assets is expected to decline to -0.55. In addition to that, Return On Capital Employed is expected to decline to -0.5. At present, DiaMedica Therapeutics' Non Current Assets Total are projected to decrease significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 1.4 M, whereas Other Assets are forecasted to decline to 1.09.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.01 | 1.43 | |
| Tangible Book Value Per Share | 1.01 | 0.68 | |
| Enterprise Value Over EBITDA | (4.12) | (4.32) | |
| Price Book Value Ratio | 5.39 | 5.12 | |
| Enterprise Value Multiple | (4.12) | (4.32) | |
| Price Fair Value | 5.39 | 5.12 | |
| Enterprise Value | 195 M | 204.8 M |
Evaluating the management effectiveness of DiaMedica Therapeutics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The DiaMedica Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Technical Drivers
As of the 26th of March, DiaMedica Therapeutics shows the Standard Deviation of 5.67, coefficient of variation of (12,140), and Mean Deviation of 3.39. DiaMedica Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.DiaMedica Therapeutics Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. DiaMedica Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for DiaMedica Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
DiaMedica Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific DiaMedica Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on DiaMedica Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases DiaMedica Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
DiaMedica Therapeutics Outstanding Bonds
DiaMedica Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. DiaMedica Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most DiaMedica bonds can be classified according to their maturity, which is the date when DiaMedica Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
DiaMedica Therapeutics Predictive Daily Indicators
DiaMedica Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of DiaMedica Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 14255.16 | |||
| Daily Balance Of Power | (0.75) | |||
| Rate Of Daily Change | 0.92 | |||
| Day Median Price | 4.78 | |||
| Day Typical Price | 4.71 | |||
| Price Action Indicator | (0.39) | |||
| Period Momentum Indicator | (0.38) | |||
| Relative Strength Index | 41.29 |
DiaMedica Therapeutics Corporate Filings
8K | 17th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 6th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 24th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 18th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 3rd of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 7th of August 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 18th of July 2024 Other Reports | ViewVerify |
DiaMedica Therapeutics Forecast Models
DiaMedica Therapeutics' time-series forecasting models are one of many DiaMedica Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary DiaMedica Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About DiaMedica Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how DiaMedica Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling DiaMedica shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as DiaMedica Therapeutics. By using and applying DiaMedica Stock analysis, traders can create a robust methodology for identifying DiaMedica entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (10.18) | (10.69) | |
| Operating Profit Margin | (12.17) | (12.78) | |
| Net Loss | (10.32) | (10.84) |
Current DiaMedica Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. DiaMedica analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. DiaMedica analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 8.0 | Strong Buy | 4 | Odds |
Most DiaMedica analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand DiaMedica stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of DiaMedica Therapeutics, talking to its executives and customers, or listening to DiaMedica conference calls.
DiaMedica Stock Analysis Indicators
DiaMedica Therapeutics stock analysis indicators help investors evaluate how DiaMedica Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading DiaMedica Therapeutics shares will generate the highest return on investment. By understating and applying DiaMedica Therapeutics stock analysis, traders can identify DiaMedica Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 4.5 M | |
| Total Stockholder Equity | 40.7 M | |
| Capital Lease Obligations | 340 K | |
| Property Plant And Equipment Net | 427 K | |
| Cash And Short Term Investments | 44.1 M | |
| Net Invested Capital | 40.7 M | |
| Cash | 3 M | |
| 200 Day M A | 4.5282 | |
| 50 Day M A | 5.885 | |
| Total Current Liabilities | 5.4 M | |
| Investments | 8.6 M | |
| Stock Based Compensation | 2.1 M | |
| Common Stock Shares Outstanding | 40.4 M | |
| Tax Provision | 30 K | |
| Free Cash Flow | -22.1 M | |
| Operating Income | -26.7 M | |
| Other Current Assets | 463 K | |
| Accounts Payable | 940 K | |
| Net Debt | -2.7 M | |
| Depreciation | 39 K | |
| Non Current Assets Total | 1.7 M | |
| Liabilities And Stockholders Equity | 46.3 M | |
| Home Category | Domestic | |
| Non Currrent Assets Other | 1.3 M |
Complementary Tools for DiaMedica Stock analysis
When running DiaMedica Therapeutics' price analysis, check to measure DiaMedica Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DiaMedica Therapeutics is operating at the current time. Most of DiaMedica Therapeutics' value examination focuses on studying past and present price action to predict the probability of DiaMedica Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DiaMedica Therapeutics' price. Additionally, you may evaluate how the addition of DiaMedica Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Stocks Directory Find actively traded stocks across global markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |